ABT Platform
)
Revolutionizing Therapeutic Interventions
Microbiome research and development is greatly influencing the way we now treat a wide range of diseases and conditions. While there are several “probiotic” products sold over the counter that claim to prevent various human diseases, very few have shown significant impact on patient outcomes.
The Scioto Activated Bacterial Therapeutics (ABT) delivery platform has been shown to enable bacteria to persist in the gut by delivering live therapeutic bacteria already in a biofilm state, providing lasting beneficial effects including a healthier microbiome. Our technology has the potential to reduce disease burden in any disorder associated with a “leaky gut,” including clostridium difficile infections, irritable bowel syndrome, diabetes, oncology and various other chronic diseases.
Therapeutic bacteria assembles inmicroparticle for prebiotic load
Biofilm formulation ready for delivery into GI
Activated biofilm is distributed throughout the GI system
){kind=icon}
Scioto’s Unique ABT Approach to Delivering Active, Live Therapeutic Bacteria
Create Biofilm Formation
Forms an activated probiotic biofilm around loaded microparticles to prime colony-forming mechanisms of bacteria
Enable Active Protection
Protects bacteria for increased survival through the GI system
Provide Enhanced Efficacy
Enhances function and mucosal thickening for a persistent beneficial effect
Our Pipeline
Optimizing Microbiome Delivery
Optimizing microbiome delivery for the benefit of children and adults with autism and GI disorders.